Details of the Drug Combination

General Information of Drug Combination (ID: DCZCUK5)

Drug Combination Name
Lonafarnib Fenretinide
Indication
Disease Entry Status REF
Head and Neck Cancer Phase 1 [1]
Component Drugs Lonafarnib   DMGM2Z6 Fenretinide   DMRD5SP
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Lonafarnib
Disease Entry ICD 11 Status REF
Hutchinson-Gilford progeria syndrome LD2B Approved [2]
Myelodysplastic syndrome 2A37 Phase 3 [3]
Hepatitis D virus infection 1E51.2 Phase 2 [4]
Non-small-cell lung cancer 2C25.Y Discontinued in Phase 3 [5]
Lonafarnib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Farnesyl protein transferase (Ftase) TTXQKM3 FNTA_HUMAN; FNTB_HUMAN Modulator [2]
------------------------------------------------------------------------------------
Lonafarnib Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [8]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [8]
------------------------------------------------------------------------------------
Lonafarnib Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Prelamin-A/C (LMNA) OT3SG7ZR LMNA_HUMAN Decreases Farnesylation [9]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Cleavage [10]
GTP-binding protein Rheb (RHEB) OTFLTSEC RHEB_HUMAN Decreases Activity [11]
------------------------------------------------------------------------------------
Indication(s) of Fenretinide
Disease Entry ICD 11 Status REF
Macular degeneration 9B78.3 Phase 3 [6]
Lymphoma 2A80-2A86 Phase 2 [7]
Peripheral T-cell lymphoma 2A90.C Phase 2 [4]
Solid tumour/cancer 2A00-2F9Z Phase 2 [7]
Tumour 2A00-2F9Z Phase 1 [7]
Fenretinide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Retinoic acid receptor (RAR) TTOD7B3 NOUNIPROTAC Modulator [19]
------------------------------------------------------------------------------------
Fenretinide Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [20]
------------------------------------------------------------------------------------
Fenretinide Interacts with 183 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 26A1 (CYP26A1) OTL1DFWV CP26A_HUMAN Increases Expression [21]
Class E basic helix-loop-helix protein 40 (BHLHE40) OTITX14U BHE40_HUMAN Increases Expression [22]
Krueppel-like factor 7 (KLF7) OTS3YVA0 KLF7_HUMAN Increases Expression [22]
Short-chain dehydrogenase/reductase 3 (DHRS3) OTSK1DTP DHRS3_HUMAN Increases Expression [22]
Low-density lipoprotein receptor (LDLR) OTH559LU LDLR_HUMAN Decreases Expression [22]
72 kDa type IV collagenase (MMP2) OT5NIWA2 MMP2_HUMAN Decreases Activity [22]
Interferon regulatory factor 1 (IRF1) OT43DI6J IRF1_HUMAN Increases Expression [22]
Bone morphogenetic protein 2 (BMP2) OT23T37S BMP2_HUMAN Increases Expression [22]
Aminopeptidase N (ANPEP) OTP3WYFD AMPN_HUMAN Decreases Activity [22]
E-selectin (SELE) OT33RZWY LYAM2_HUMAN Increases Expression [22]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3) OTC1UOHP ATF3_HUMAN Increases Expression [22]
C-X-C motif chemokine 2 (CXCL2) OTEJCYMY CXCL2_HUMAN Increases Expression [22]
C-X-C motif chemokine 3 (CXCL3) OTSL94KH CXCL3_HUMAN Increases Expression [22]
Hematopoietic progenitor cell antigen CD34 (CD34) OT1MOFLZ CD34_HUMAN Decreases Expression [22]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Increases Expression [22]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Increases Expression [22]
Nuclear receptor-interacting protein 1 (NRIP1) OTIZOJQV NRIP1_HUMAN Increases Expression [22]
Heat shock-related 70 kDa protein 2 (HSPA2) OTSDET7B HSP72_HUMAN Decreases Expression [22]
C-C motif chemokine 20 (CCL20) OTUCJY4N CCL20_HUMAN Increases Expression [22]
Large neutral amino acids transporter small subunit 1 (SLC7A5) OT2WPVXD LAT1_HUMAN Increases Expression [22]
Trefoil factor 3 (TFF3) OTJJDRTU TFF3_HUMAN Decreases Expression [22]
CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 (ST3GAL1) OTFCO8QX SIA4A_HUMAN Increases Expression [22]
Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 protein (HERPUD1) OT9EROL6 HERP1_HUMAN Increases Expression [22]
Retinoic acid-induced protein 3 (GPRC5A) OTPOCWR7 RAI3_HUMAN Increases Expression [22]
Semaphorin-3C (SEMA3C) OTEGUY7F SEM3C_HUMAN Increases Expression [22]
Growth/differentiation factor 15 (GDF15) OTWQN50N GDF15_HUMAN Increases Expression [22]
Protein DEPP1 (DEPP1) OTB36PHJ DEPP1_HUMAN Increases Expression [22]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Increases Expression [22]
E3 ubiquitin-protein ligase TRIM33 (TRIM33) OT0KS4J7 TRI33_HUMAN Increases Expression [22]
Protein phosphatase 1 regulatory subunit 3C (PPP1R3C) OTEU05TX PPR3C_HUMAN Decreases Expression [22]
Pirin (PIR) OT8ALXHU PIR_HUMAN Increases Expression [12]
Claudin-4 (CLDN4) OT9C4PZ4 CLD4_HUMAN Increases Expression [12]
Regulator of G-protein signaling 5 (RGS5) OTUY0Q2I RGS5_HUMAN Increases Expression [12]
Claudin-3 (CLDN3) OT71MN9S CLD3_HUMAN Increases Expression [12]
Double-strand-break repair protein rad21 homolog (RAD21) OTQS84ZF RAD21_HUMAN Decreases Expression [12]
Trafficking kinesin-binding protein 2 (TRAK2) OTXVA7FN TRAK2_HUMAN Increases Expression [12]
Securin (PTTG1) OTIMYS4W PTTG1_HUMAN Decreases Expression [12]
Alpha-crystallin B chain (CRYAB) OTY4JGYU CRYAB_HUMAN Increases Expression [12]
Plasminogen activator inhibitor 2 (SERPINB2) OT72QLZB PAI2_HUMAN Decreases Expression [12]
Non-histone chromosomal protein HMG-17 (HMGN2) OTN20MEF HMGN2_HUMAN Decreases Expression [12]
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Decreases Expression [12]
Amino acid transporter heavy chain SLC3A2 (SLC3A2) OTBR33M9 4F2_HUMAN Increases Expression [12]
Signal recognition particle 19 kDa protein (SRP19) OT8RP8JB SRP19_HUMAN Decreases Expression [12]
Fructose-bisphosphate aldolase C (ALDOC) OTEC13I5 ALDOC_HUMAN Increases Expression [12]
Histone H2A.Z (H2AZ1) OT3KJJNQ H2AZ_HUMAN Decreases Expression [12]
Proliferating cell nuclear antigen (PCNA) OTHZ1RIA PCNA_HUMAN Decreases Expression [12]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) OTRFV19J ATF4_HUMAN Increases Expression [12]
Lymphocyte function-associated antigen 3 (CD58) OTIUGMGS LFA3_HUMAN Decreases Expression [12]
Alanine--glyoxylate aminotransferase (AGXT) OTIPTH3Q AGT1_HUMAN Increases Expression [12]
Midkine (MDK) OTF24HKC MK_HUMAN Increases Expression [12]
Insulin-like growth factor-binding protein 5 (IGFBP5) OTRE5V0C IBP5_HUMAN Decreases Expression [12]
NKG2-C type II integral membrane protein (KLRC2) OTT4N86S NKG2C_HUMAN Increases Expression [12]
Peptidyl-prolyl cis-trans isomerase F, mitochondrial (PPIF) OTRA8ZVE PPIF_HUMAN Increases Expression [12]
Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial (DUT) OT0THBVA DUT_HUMAN Decreases Expression [12]
Very long-chain specific acyl-CoA dehydrogenase, mitochondrial (ACADVL) OT50L4XB ACADV_HUMAN Increases Expression [12]
6-phosphogluconate dehydrogenase, decarboxylating (PGD) OTVG296F 6PGD_HUMAN Increases Expression [12]
Cysteine-rich protein 2 (CRIP2) OTVVJSYX CRIP2_HUMAN Decreases Expression [12]
Apolipoprotein C-IV (APOC4) OTE8ZUXY APOC4_HUMAN Decreases Expression [12]
Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-11 (GNG11) OTHIXBGW GBG11_HUMAN Decreases Expression [12]
ETS-related transcription factor Elf-3 (ELF3) OTUTLEQO ELF3_HUMAN Increases Expression [12]
Neutrophil gelatinase-associated lipocalin (LCN2) OTSB42BR NGAL_HUMAN Increases Expression [12]
Nucleobindin-2 (NUCB2) OTHO6JWN NUCB2_HUMAN Increases Expression [12]
Peptidyl-prolyl cis-trans isomerase FKBP4 (FKBP4) OTPV1D60 FKBP4_HUMAN Decreases Expression [12]
Aldo-keto reductase family 1 member C1 (AKR1C1) OTQKR4CM AK1C1_HUMAN Increases Expression [12]
Tumor protein D53 (TPD52L1) OTSA6U0I TPD53_HUMAN Increases Expression [12]
Single-stranded DNA-binding protein 4 (SSBP4) OTTK1ZHQ SSBP4_HUMAN Decreases Expression [12]
Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B) OTUYHB84 MLP3B_HUMAN Increases Expression [12]
Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 (NUCKS1) OTL4VJC5 NUCKS_HUMAN Decreases Expression [12]
Heat shock protein beta-8 (HSPB8) OT0I83YS HSPB8_HUMAN Increases Expression [12]
BTB/POZ domain-containing protein KCTD3 (KCTD3) OT6EGR42 KCTD3_HUMAN Decreases Expression [12]
Methylated-DNA--protein-cysteine methyltransferase (MGMT) OT40A9WH MGMT_HUMAN Increases Expression [23]
Superoxide dismutase (SOD1) OT39TA1L SODC_HUMAN Increases Expression [24]
Glutathione peroxidase 1 (GPX1) OTE2O72Q GPX1_HUMAN Increases Expression [24]
Glucose-6-phosphate 1-dehydrogenase (G6PD) OT300SMK G6PD_HUMAN Increases Expression [24]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Increases Phosphorylation [24]
Ribosomal protein S6 kinase alpha-2 (RPS6KA2) OTIOYUSU KS6A2_HUMAN Increases Phosphorylation [24]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Increases Expression [24]
Acyl carrier protein, mitochondrial (NDUFAB1) OTF906UR ACPM_HUMAN Affects Expression [13]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [25]
Mitochondrial import inner membrane translocase subunit Tim23 (TIMM23) OTAAS85T TIM23_HUMAN Affects Expression [13]
NADH dehydrogenase 1 alpha subcomplex subunit 1 (NDUFA1) OTKBUQXP NDUA1_HUMAN Affects Expression [13]
CASP8 and FADD-like apoptosis regulator (CFLAR) OTX14BAS CFLAR_HUMAN Decreases Expression [26]
NADH dehydrogenase 1 beta subcomplex subunit 3 (NDUFB3) OTDV12IF NDUB3_HUMAN Affects Expression [13]
Germinal-center associated nuclear protein (MCM3AP) OT895FEC GANP_HUMAN Affects Expression [13]
Nuclear protein 1 (NUPR1) OT4FU8C0 NUPR1_HUMAN Affects Expression [27]
Protein phosphatase 1 regulatory subunit 15A (PPP1R15A) OTYG179K PR15A_HUMAN Increases Expression [27]
Isocitrate dehydrogenase cytoplasmic (IDH1) OT4DLHC8 IDHC_HUMAN Affects Expression [13]
PRA1 family protein 3 (ARL6IP5) OTYZ6BEQ PRAF3_HUMAN Affects Expression [28]
NADH dehydrogenase 1 beta subcomplex subunit 6 (NDUFB6) OTIXNT91 NDUB6_HUMAN Affects Expression [13]
NADH dehydrogenase 1 beta subcomplex subunit 2, mitochondrial (NDUFB2) OT4717TF NDUB2_HUMAN Affects Expression [13]
Brain mitochondrial carrier protein 1 (SLC25A14) OT1ZQSKS UCP5_HUMAN Increases Expression [13]
NADH dehydrogenase 1 alpha subcomplex subunit 10, mitochondrial (NDUFA10) OTBURQ3A NDUAA_HUMAN Affects Expression [13]
Mitochondrial import receptor subunit TOM40 homolog (TOMM40) OTZDQ29F TOM40_HUMAN Affects Expression [13]
L-lactate dehydrogenase A chain (LDHA) OTN7K4XB LDHA_HUMAN Decreases Expression [13]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Increases Expression [13]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [29]
Retinol-binding protein 4 (RBP4) OTL9RBH5 RET4_HUMAN Affects Binding [30]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Decreases Expression [29]
Insulin-like growth factor I (IGF1) OTIIZR61 IGF1_HUMAN Decreases Activity [31]
Eukaryotic translation initiation factor 2 subunit 1 (EIF2S1) OTM0GDTP IF2A_HUMAN Increases Phosphorylation [27]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Expression [32]
Keratin, type I cytoskeletal 18 (KRT18) OTVLQFIP K1C18_HUMAN Increases Expression [33]
Keratin, type II cytoskeletal 8 (KRT8) OTTM4X11 K2C8_HUMAN Increases Expression [33]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Increases Expression [13]
DNA excision repair protein ERCC-1 (ERCC1) OTNPYQHI ERCC1_HUMAN Increases Expression [32]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [34]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Decreases Cleavage [18]
Retinoic acid receptor alpha (RARA) OT192V9V RARA_HUMAN Increases Expression [31]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [29]
Microtubule-associated protein tau (MAPT) OTMTP2Z7 TAU_HUMAN Increases Expression [13]
Retinoic acid receptor beta (RARB) OT367U3E RARB_HUMAN Increases Expression [35]
Endoplasmic reticulum chaperone BiP (HSPA5) OTFUIRAO BIP_HUMAN Increases Expression [15]
Retinoic acid receptor gamma (RARG) OT8LHMDH RARG_HUMAN Decreases Expression [36]
Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial (MTHFD2) OT1LQSGX MTDC_HUMAN Affects Expression [13]
NAD(P)H dehydrogenase 1 (NQO1) OTZGGIVK NQO1_HUMAN Affects Expression [13]
NADH dehydrogenase 1 beta subcomplex subunit 7 (NDUFB7) OT2CHQQ1 NDUB7_HUMAN Affects Expression [13]
Glutathione peroxidase 2 (GPX2) OTXI2NTI GPX2_HUMAN Increases Expression [37]
Retinoic acid receptor RXR-alpha (RXRA) OTP1TBDM RXRA_HUMAN Increases Expression [13]
Neutrophil cytosol factor 2 (NCF2) OTAUW7L2 NCF2_HUMAN Increases Expression [32]
Cyclin-A2 (CCNA2) OTPHHYZJ CCNA2_HUMAN Decreases Expression [38]
Nuclear receptor subfamily 4immunitygroup A member 1 (NR4A1) OTGP6GA4 NR4A1_HUMAN Increases Expression [39]
Tyrosine-protein kinase JAK1 (JAK1) OT0X3D17 JAK1_HUMAN Increases Expression [32]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [33]
Interleukin-4 receptor subunit alpha (IL4R) OTTXOTCW IL4RA_HUMAN Decreases Expression [13]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A) OTDRV63V GA45A_HUMAN Increases Expression [13]
Paired box protein Pax-6 (PAX6) OTOC9876 PAX6_HUMAN Decreases Expression [17]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Increases Phosphorylation [40]
Calreticulin (CALR) OTYD2TR1 CALR_HUMAN Increases Expression [15]
Calnexin (CANX) OTYP1F6J CALX_HUMAN Increases Expression [15]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Increases Phosphorylation [40]
Retinoic acid receptor RXR-beta (RXRB) OTNPDXG2 RXRB_HUMAN Increases Expression [13]
Protein disulfide-isomerase A3 (PDIA3) OTHPQ0Q3 PDIA3_HUMAN Increases Expression [15]
Peroxisome proliferator-activated receptor gamma (PPARG) OTHMARHO PPARG_HUMAN Increases Activity [41]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [38]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Decreases Expression [18]
Caspase-2 (CASP2) OTUDYSPP CASP2_HUMAN Increases Activity [34]
Cyclin-dependent kinase inhibitor 2A (CDKN2A) OTN0ZWAE CDN2A_HUMAN Increases Expression [13]
Mitogen-activated protein kinase 8 (MAPK8) OTEREYS5 MK08_HUMAN Increases Activity [40]
Dual specificity mitogen-activated protein kinase kinase 4 (MAP2K4) OTZPZX11 MP2K4_HUMAN Increases Phosphorylation [40]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Increases Expression [42]
Dual specificity mitogen-activated protein kinase kinase 3 (MAP2K3) OTI2OREX MP2K3_HUMAN Increases Phosphorylation [40]
Retinoic acid receptor RXR-gamma (RXRG) OT254B09 RXRG_HUMAN Decreases Expression [13]
Glutamate--cysteine ligase catalytic subunit (GCLC) OTESDI4D GSH1_HUMAN Increases Expression [35]
Nuclear receptor subfamily 2 group C member 2 (NR2C2) OTDZWVOJ NR2C2_HUMAN Increases Expression [13]
Breast cancer type 2 susceptibility protein (BRCA2) OTF1XSV1 BRCA2_HUMAN Decreases Expression [13]
NADH dehydrogenase 1 alpha subcomplex subunit 8 (NDUFA8) OTBO0YKI NDUA8_HUMAN Affects Expression [13]
Dual specificity mitogen-activated protein kinase kinase 6 (MAP2K6) OTK13JKC MP2K6_HUMAN Increases Phosphorylation [40]
Paired mesoderm homeobox protein 1 (PRRX1) OTTZK5G8 PRRX1_HUMAN Increases Expression [13]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Increases Activity [43]
Growth factor receptor-bound protein 2 (GRB2) OTOP7LTE GRB2_HUMAN Increases Expression [32]
Transcription factor A, mitochondrial (TFAM) OTXXV5V7 TFAM_HUMAN Affects Expression [13]
Heat shock factor protein 1 (HSF1) OTYNJ4KP HSF1_HUMAN Increases Activity [44]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Decreases Expression [13]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [18]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [45]
Retinoblastoma-like protein 2 (RBL2) OTBQSOE6 RBL2_HUMAN Increases Expression [32]
Histone-binding protein RBBP4 (RBBP4) OTG3BT3M RBBP4_HUMAN Increases Expression [13]
TP53-binding protein 1 (TP53BP1) OTL8879S TP53B_HUMAN Increases Expression [13]
TNF receptor-associated factor 1 (TRAF1) OTTLM5RU TRAF1_HUMAN Decreases Expression [26]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Decreases Expression [26]
Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1) OTXEE550 APR_HUMAN Increases Expression [46]
Cyclin-dependent kinase 5 activator 1 (CDK5R1) OTJELWK0 CD5R1_HUMAN Decreases Expression [13]
Mitogen-activated protein kinase 14 (MAPK14) OT5TCO3O MK14_HUMAN Increases Activity [40]
Bcl-2-related protein A1 (BCL2A1) OTWRYSNA B2LA1_HUMAN Decreases Expression [26]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Increases Expression [25]
NADH dehydrogenase 1 alpha subcomplex subunit 5 (NDUFA5) OTR848KZ NDUA5_HUMAN Affects Expression [13]
NADH dehydrogenase 1 alpha subcomplex subunit 9, mitochondrial (NDUFA9) OTMKQJJ8 NDUA9_HUMAN Affects Expression [13]
DnaJ homolog subfamily C member 10 (DNAJC10) OTD2EG0R DJC10_HUMAN Increases Expression [15]
Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2) OT0HFPCD LIRB2_HUMAN Decreases Expression [13]
Bcl-2-binding component 3, isoforms 3/4 (BBC3) OTUAXDAY BBC3B_HUMAN Increases Expression [47]
BRCA1-associated RING domain protein 1 (BARD1) OTTC0Z9Y BARD1_HUMAN Decreases Expression [13]
Mitochondrial intermediate peptidase (MIPEP) OTB2IHCT MIPEP_HUMAN Affects Expression [13]
BAG family molecular chaperone regulator 1 (BAG1) OTRQNIA4 BAG1_HUMAN Affects Localization [17]
Eukaryotic translation initiation factor 2A (EIF2A) OTWXELQP EIF2A_HUMAN Increases Phosphorylation [15]
Apoptosis facilitator Bcl-2-like protein 14 (BCL2L14) OT87E7HW B2L14_HUMAN Increases Expression [13]
Isoleucine--tRNA ligase, mitochondrial (IARS2) OTDX4SCA SYIM_HUMAN Affects Expression [13]
RB-associated KRAB zinc finger protein (RBAK) OTYJ6EAU RBAK_HUMAN Increases Expression [13]
Mitochondrial carrier homolog 1 (MTCH1) OT0F9ADF MTCH1_HUMAN Affects Expression [13]
FAS-associated factor 1 (FAF1) OTGAMLM4 FAF1_HUMAN Decreases Expression [13]
Tumor necrosis factor ligand superfamily member 13B (TNFSF13B) OTND26XR TN13B_HUMAN Increases Expression [13]
Mediator of RNA polymerase II transcription subunit 16 (MED16) OT8SCI48 MED16_HUMAN Decreases Expression [13]
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3) OT0DZGY4 E2AK3_HUMAN Decreases Response To Substance [27]
Galactosylceramide sulfotransferase (GAL3ST1) OTSFFZRD G3ST1_HUMAN Decreases Response To Substance [42]
------------------------------------------------------------------------------------
⏷ Show the Full List of 183 DOT(s)

References

1 ClinicalTrials.gov (NCT00102635) 4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
3 ClinicalTrials.gov (NCT00109538) Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED). U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8024).
6 ClinicalTrials.gov (NCT00003075) Fenretinide in Treating Patients With Cervical Neoplasia. U.S. National Institutes of Health.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar). Drug Metab Dispos. 2006 Apr;34(4):628-35.
9 Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma. Leuk Res. 2007 Mar;31(3):341-52. doi: 10.1016/j.leukres.2006.07.018. Epub 2006 Sep 22.
10 The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Blood. 2005 Dec 15;106(13):4322-9. doi: 10.1182/blood-2005-06-2584. Epub 2005 Aug 23.
11 Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells. Cancer Lett. 2010 Nov 1;297(1):117-25. doi: 10.1016/j.canlet.2010.05.004.
12 Regulation of lipocalin-2 gene by the cancer chemopreventive retinoid 4-HPR. Int J Cancer. 2006 Oct 1;119(7):1599-606.
13 4-HPR modulates gene expression in ovarian cells. Int J Cancer. 2006 Sep 1;119(5):1005-13. doi: 10.1002/ijc.21797.
14 Cholecalciferol (vitamin D3) and the retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) are synergistic for chemoprevention of prostate cancer. J Exp Ther Oncol. 2006;5(4):323-33.
15 Targeting homeostatic mechanisms of endoplasmic reticulum stress to increase susceptibility of cancer cells to fenretinide-induced apoptosis: the role of stress proteins ERdj5 and ERp57. Br J Cancer. 2007 Apr 10;96(7):1062-71. doi: 10.1038/sj.bjc.6603672. Epub 2007 Mar 13.
16 [The role of reactive oxygen species in N-[4-hydroxyphenyl] retinamide induced apoptosis in bladder cancer cell lineT24]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2005 Jun;23(3):191-4.
17 Fenretinide-induced neuronal differentiation of ARPE-19 human retinal pigment epithelial cells is associated with the differential expression of Hsp70, 14-3-3, pax-6, tubulin beta-III, NSE, and bag-1 proteins. Mol Vis. 2006 Nov 1;12:1355-63.
18 Anti-proliferative activity of fenretinide in human hepatoma cells in vitro and in vivo. Anticancer Drugs. 2007 Jan;18(1):47-53. doi: 10.1097/CAD.0b013e32800feeb5.
19 National Cancer Institute Drug Dictionary (drug id 39582).
20 Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases. Br J Pharmacol. 2011 Feb;162(4):989-99.
21 Nuclear retinoid receptors are involved in N-(4-hydroxyphenyl) retinamide (Fenretinide)-induced gene expression and growth inhibition in HL-60 acute myeloid leukemia cells. Leuk Lymphoma. 2004 May;45(5):979-85.
22 The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide. Clin Cancer Res. 2005 Jun 15;11(12):4610-9.
23 Increased expression of the MGMT repair protein mediated by cysteine prodrugs and chemopreventative natural products in human lymphocytes and tumor cell lines. Carcinogenesis. 2007 Feb;28(2):378-89.
24 Glycogen synthase kinase 3 regulates cell death and survival signaling in tumor cells under redox stress. Neoplasia. 2014 Sep;16(9):710-22.
25 Fenretinide up-regulates DR5/TRAIL-R2 expression via the induction of the transcription factor CHOP and combined treatment with fenretinide and TRAIL induces synergistic apoptosis in colon cancer cell lines. Int J Oncol. 2007 Mar;30(3):679-87.
26 N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products. Cancer Res. 2005 Oct 15;65(20):9555-65. doi: 10.1158/0008-5472.CAN-05-1585.
27 Regulation of endoplasmic reticulum stress-induced cell death by ATF4 in neuroectodermal tumor cells. J Biol Chem. 2010 Feb 26;285(9):6091-100. doi: 10.1074/jbc.M109.014092. Epub 2009 Dec 18.
28 Comparing the effect of ATRA, 4-HPR, and CD437 in bladder cancer cells. Front Biosci. 2006 Sep 1;11:2007-16. doi: 10.2741/1942.
29 Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated bcl-2. Blood. 1995 Jan 15;85(2):359-67.
30 Fenretinide derivatives act as disrupters of interactions of serum retinol binding protein (sRBP) with transthyretin and the sRBP receptor. J Med Chem. 2011 Jul 14;54(13):4378-87. doi: 10.1021/jm200256g. Epub 2011 Jun 7.
31 Induction of apoptosis in primary meningioma cultures by fenretinide. Cancer Res. 2005 Feb 15;65(4):1547-53. doi: 10.1158/0008-5472.CAN-04-0786.
32 Identification of retinoid-modulated proteins in squamous carcinoma cells using high-throughput immunoblotting. Cancer Res. 2004 Apr 1;64(7):2439-48. doi: 10.1158/0008-5472.can-03-2643.
33 Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. Br J Cancer. 2007 Apr 23;96(8):1204-15. doi: 10.1038/sj.bjc.6603705. Epub 2007 Mar 27.
34 N-(4-hydroxyphenyl)retinamide induces apoptosis in human retinal pigment epithelial cells: retinoic acid receptors regulate apoptosis, reactive oxygen species generation, and the expression of heme oxygenase-1 and Gadd153. J Cell Physiol. 2006 Dec;209(3):854-65. doi: 10.1002/jcp.20774.
35 Enrichment of Nur77 mediated by retinoic acid receptor leads to apoptosis of human hepatocellular carcinoma cells induced by fenretinide and histone deacetylase inhibitors. Hepatology. 2011 Mar;53(3):865-74. doi: 10.1002/hep.24101. Epub 2011 Feb 11.
36 Breast cancer progression in MCF10A series of cell lines is associated with alterations in retinoic acid and retinoid X receptors and with differential response to retinoids. Int J Oncol. 2004 Oct;25(4):961-71.
37 Expression of gastrointestinal glutathione peroxidase is inversely correlated to the presence of hepatitis C virus subgenomic RNA in human liver cells. J Biol Chem. 2005 Mar 11;280(10):8831-41. doi: 10.1074/jbc.M413730200. Epub 2004 Dec 28.
38 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines. Cancer Res. 2006 Mar 15;66(6):3238-47. doi: 10.1158/0008-5472.CAN-05-3362.
39 Induction and intracellular localization of Nur77 dictate fenretinide-induced apoptosis of human liver cancer cells. Biochem Pharmacol. 2010 Apr 1;79(7):948-54. doi: 10.1016/j.bcp.2009.11.004. Epub 2009 Nov 11.
40 N-(4-hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells. Oncogene. 2006 May 4;25(19):2785-94. doi: 10.1038/sj.onc.1209303.
41 PPAR activation and decreased proliferation in oral carcinoma cells with 4-HPR. Otolaryngol Head Neck Surg. 2005 Nov;133(5):695-701. doi: 10.1016/j.otohns.2005.07.019.
42 Inhibitory effects of N-(4-hydrophenyl) retinamide on liver cancer and malignant melanoma cells. World J Gastroenterol. 2005 Oct 7;11(37):5763-9. doi: 10.3748/wjg.v11.i37.5763.
43 Mechanism of 4-HPR-induced apoptosis in glioma cells: evidences suggesting role of mitochondrial-mediated pathway and endoplasmic reticulum stress. Carcinogenesis. 2006 Oct;27(10):2047-58. doi: 10.1093/carcin/bgl051. Epub 2006 May 4.
44 A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
45 Retinamide-induced apoptosis in glioblastomas is associated with down-regulation of Bcl-xL and Bcl-2 proteins. J Neurooncol. 2005 Sep;74(3):225-32. doi: 10.1007/s11060-005-7305-z.
46 Role of Noxa in p53-independent fenretinide-induced apoptosis of neuroectodermal tumours. Apoptosis. 2007 Mar;12(3):613-22. doi: 10.1007/s10495-006-0020-1.
47 BBC3 mediates fenretinide-induced cell death in neuroblastoma. Oncogene. 2005 Dec 1;24(54):7976-83. doi: 10.1038/sj.onc.1208947.